Fulcrum Therapeutics (FULC) Assets Average (2019 - 2026)

Fulcrum Therapeutics (FULC) has 8 years of Assets Average data on file, last reported at $356.5 million in Q1 2026.

• On a quarterly basis, Assets Average rose 41.66% year-over-year to $356.5 million in Q1 2026; TTM through Mar 2026 was $356.5 million, a 41.66% increase from a year earlier, with the FY2025 full-year figure at $313.5 million, up 20.95% from the prior year.
• Assets Average for Q1 2026 stood at $356.5 million, up from $290.6 million in the prior quarter.
• Over the last five years, Assets Average for FULC reached as high as $356.5 million in Q1 2026 and fell as low as $207.7 million in Q2 2022.
• Historically, Assets Average has averaged $262.2 million across 5 years, with a median of $263.4 million in 2024.
• Across the five-year window, Assets Average soared 59.15% in 2022 and declined 22.6% in 2025, its largest moves.
• Year by year, Assets Average stood at $237.2 million in 2022, then climbed by 13.08% to $268.3 million in 2023, then rose by 0.59% to $269.9 million in 2024, then rose by 7.67% to $290.6 million in 2025, then gained by 22.7% to $356.5 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $356.5 million in Q1 2026, $290.6 million in Q4 2025, and $221.8 million in Q3 2025.